검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rimiducid |
Overview Company | Bellicum Pharmaceuticals |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.. Antidisialoganglioside (GD2), third-generation chimeric antigen receptor (CAR) T cells (GD2-CART01) have shown encouraging efficacy in children with high-risk metastatic, relapsed, or refractory neuroblastoma in the interim analysis of a phase 1/2 clinical trial. We now present the final results obtained in all 35 patients e… |
Toxicology CRS | Reported |
Clinical OS | 8 |
Clinical Result source | ClinicalTrials.gov NCT03733249 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rimiducid |
Overview Company | Bellicum Pharmaceuticals |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.. Antidisialoganglioside (GD2), third-generation chimeric antigen receptor (CAR) T cells (GD2-CART01) have shown encouraging efficacy in children with high-risk metastatic, relapsed, or refractory neuroblastoma in the interim analysis of a phase 1/2 clinical trial. We now present the final results obtained in all 35 patients e… |
Toxicology CRS | Reported |
Clinical OS | 8 |
Clinical Result source | ClinicalTrials.gov NCT03733249 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교